In the ever-evolving landscape of venture funding, a notable shift has occurred in recent years, with increased attention paid to technology-enabled women’s health products, colloquially known as the femtech market. Despite receiving a mere 2% of the $41.2 billion allocated to healthcare innovators in 2023, the sector has shown remarkable resilience and potential for growth.
Deloitte’s research paints an intriguing picture: while the overall health tech market experienced a 27% decline in venture funding between 2022 and 2023, investments in women’s health companies bucked the trend, registering a 5% increase. This upward trajectory is further corroborated by data from FemHealth Insights, which reveals that over 60% of the current roster of women’s health startups were established between 2018 and 2022.
The femtech market has undergone a significant transformation, expanding its focus beyond pregnancy and fertility to address a broader spectrum of issues, including menopause, pelvic health, and mental well-being. This diversification has caught the eye of several prominent investors, including global value-oriented and event-driven hedge fund Armistice Capital, led by Steven Boyd.
Armistice Capital has emerged as a critical player in the femtech investment arena. The fund’s strategic moves exemplify its position as the top investor in Aspira Women’s Health Inc. According to Fintel, Armistice Capital disclosed ownership of 1,157,000 shares valued at $3,586,700 as of March 31, 2024.
Aspire Women’s Health has significantly progressed in developing AI-powered, non-invasive tests for gynecologic diseases. Their flagship products, OvaWatch and Ova1Plus, are designed to revolutionize ovarian cancer risk assessment and diagnosis. The company is also making headway in creating a non-invasive test for endometriosis, which affects millions of women worldwide.
Steven Boyd’s Armistice Capital has not limited its focus to femtech alone. The fund has demonstrated a keen interest in broader biotech research, particularly in areas that intersect with women’s health. In 2023, Armistice participated in a private placement for Spruce Biosciences, a late-stage biopharmaceutical company. Spruce’s tildacerfont, a novel oral antagonist, shows promise in addressing polycystic ovary syndrome (PCOS) symptoms by potentially reducing adrenal androgen production.
Armistice Capital’s investment strategy extends to companies tackling other critical health issues. The fund has invested in Bone Biologics Corporation, whose bone regeneration technology could significantly impact osteoporosis treatment—a condition that disproportionately affects women.
Beyond women’s health, Steven Boyd’s Armistice Capital has shown a growing interest in ocular research and treatments. The fund has strategically invested in companies like Eyenovia, which is developing innovative ophthalmic drug delivery systems. According to MarketBeat, Armistice Capital purchased 3,087,021 shares of Eyenovia in the third quarter of 2023, representing about 8.08% ownership.
Armistice Capital has also participated in a private placement for Outlook Therapeutics, a biopharmaceutical company developing a formulation to treat retinal diseases. The deal, which included other investors like Great Point Partners and Woodline Partners, generated approximately $60 million in upfront gross proceeds.
Similarly, Armistice Capital took part in a private placement for GenSight Biologics, a biotech company developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. This investment underscores Armistice’s commitment to supporting groundbreaking research in diverse areas of medical science.
Through Armistice Capital, Steven Boyd has positioned the fund as a significant player in the evolving landscape of health tech investments. By focusing on areas such as women’s health and ocular research, Armistice seeks financial returns and supports developing potentially life-changing medical technologies.
As the femtech market continues to expand and diversify, and as ocular research advances, Steven Boyd’s Armistice Capital appears well-positioned to capitalize on these trends while contributing to meaningful progress in healthcare innovation. The fund’s strategic investments reflect a nuanced understanding of the healthcare sector’s evolving needs and the potential for technology to address long-standing medical challenges.